Ductal Carcinoma In Situ: What Can We Learn from Clinical TrialsReport as inadecuate

Ductal Carcinoma In Situ: What Can We Learn from Clinical Trials - Download this document for free, or read online. Document in PDF available to download.

International Journal of Surgical OncologyVolume 2012 2012, Article ID 296829, 7 pages

Review Article

Department of Surgery, Senology Unit, San Giovanni Addolorata Hospital, Via Amba-Aradam 9, 00184 Rome, Italy

Division of Plastic and Reconstructive Surgery, University Campus Bio-Medico, 00128 Rome, Italy

Department of Radiotherapy, San Giovanni Addolorata Hospital, 00184 Rome, Italy

Department of Radiology, San Giovanni Addolorata Hospital, 00184 Rome, Italy

Received 13 December 2011; Accepted 22 February 2012

Academic Editor: Virgilio Sacchini

Copyright © 2012 Lucio Fortunato et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Ductal Carcinoma in situ has been diagnosed more frequently in the last few years and now accounts for approximately one-fourth of all treated breast cancers. Traditionally, this disease has been treated with total mastectomy, but conservative surgery has become increasingly used in the absence of unfavourable clinical conditions, if a negative excision margin can be achieved. It is controversial whether subgroups of patients with favourable in situ tumors could be managed by conservative surgery alone, without radiation. As the disease is diagnosed more frequently in younger patients, these issues are very relevant, and much research has focused on this topic in the last two decades. We reviewed randomized trials regarding adjuvant radiation after breast-conservative surgery and compared data with available retrospective studies.

Author: Lucio Fortunato, Igor Poccia, Ugo de Paula, and Elena Santini

Source: https://www.hindawi.com/


Related documents